Health & Research Goals
Cagrilintide (AM833)
Cagrilintide
Cagrilintide is a long-acting, lipidated dual amylin and calcitonin receptor agonist (DACRA) engineered by Novo Nordisk as an inve…
Primary Description
Cagrilintide is a long-acting, lipidated dual amylin and calcitonin receptor agonist (DACRA) engineered by Novo Nordisk as an investigational treatment for obesity. It mimics the pancreatic hormone amylin — co-released with insulin — to reduce hunger, slow gastric emptying, and modulate postprandial glucose. The biohacker and metabolic optimization community has adopted it primarily for its powerful satiety effects and its synergy with GLP-1 receptor agonists like semaglutide in the CagriSema combination protocol.
Key Benefits
- Enhanced weight loss
- Appetite control
- Glycemic control
Lipidation via a C-20 fatty diacid and alpha-glutamyl spacer enables albumin binding, which confers once-weekly dosing stability. Structural modifications (Pro25, Pro28, Pro29 substitutions) prevent amyloid fibril formation seen with native amylin.
Demonstrated Effects
- Significant reduction in body weight — approximately 11.8% over 68 weeks as monotherapy at 2.4 mg/week
- Additive weight loss effect when combined with semaglutide (CagriSema): up to 22.7% body weight reduction in REDEFINE 1
- Reduces hunger and promotes satiety by activating amylin receptors (AMY1R, AMY2R, AMY3R) in the hypothalamus
- Slows gastric emptying, blunting postprandial glucose spikes
- Modulates glucagon secretion, supporting glycemic control
- Improves HbA1c in type 2 diabetes — 73.5% of CagriSema patients achieved HbA1c ≤6.5% in REDEFINE 2
- Shifts eating behavior toward smaller, more satisfying portions without pure willpower-based caloric restriction
- Potential cardiovascular metabolic benefits from sustained weight loss
Proposed Mechanisms of Action
1. Dual Amylin and Calcitonin Receptor Agonism (DACRA)
Cagrilintide activates all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) — heterodimers of the calcitonin receptor (CTR) paired with RAMP1, RAMP2, or RAMP3 accessory subunits — as well as the calcitonin receptor itself. All receptors signal through Gs-coupled pathways. The F23 residue anchors the peptide at the receptor transmembrane bundle, and an intramolecular E14-R17 salt bridge stabilizes the active helical conformation.
Drives the primary appetite suppression and satiety effects, as well as glucagon suppression and gastric motility slowing.
2. Albumin Binding via Fatty Acid Lipidation
A C-20 fatty diacid attached via an alpha-glutamyl spacer enables cagrilintide to bind reversibly to serum albumin after subcutaneous injection, dramatically extending its half-life compared to native amylin or pramlintide.
Converts a short-acting hormone into a once-weekly injectable, enabling sustained receptor engagement and consistent appetite modulation throughout the week.
3. Hypothalamic Appetite Circuit Modulation
Amylin receptors in the area postrema and nucleus tractus solitarius relay satiety signals to the hypothalamus. Cagrilintide amplifies these signals beyond what endogenous amylin achieves, shifting the body's energy homeostasis setpoint.
Produces genuine reduction in appetite and food intake rather than willpower-dependent caloric restriction. Users report feeling satisfied with substantially smaller meals.
Research Evidence & Clinical Data
Investigated Applications
Weight Loss and Metabolic Optimization
Anecdotal: HighThe primary use case in self-experimenting communities. Users report genuine satiety improvements — feeling satisfied with smaller portions rather than fighting hunger signals. The 'low and slow' titration approach used in clinical trials has been adopted by community members to minimize GI side effects.
Preclinical basis: Dual activation of amylin and calcitonin receptors drives appetite suppression via hypothalamic pathways. Albumin binding via C-20 fatty diacid provides the extended once-weekly pharmacokinetic profile.
GLP-1 Combination Protocol (CagriSema)
Anecdotal: HighThe CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) is increasingly discussed as a step up from GLP-1 monotherapy for those who have plateaued on semaglutide alone. Community reports describe superior appetite suppression compared to semaglutide alone.
Preclinical basis: Amylin and GLP-1 act on separate but complementary hypothalamic pathways. Phase 3 REDEFINE 1 demonstrated 22.7% weight loss with the combination vs 16.1% with semaglutide alone and 11.8% with cagrilintide alone.
Glycemic Control in Type 2 Diabetes
Anecdotal: ModerateLess commonly self-administered for diabetes specifically, but metabolically focused biohackers note its postprandial glucose-dampening effects. The CagriSema combination showed dramatic HbA1c improvements in REDEFINE 2 clinical data.
Preclinical basis: Amylin receptor activation suppresses glucagon secretion and slows gastric emptying, reducing the rate of glucose appearance in circulation after meals.
Scientific References
- 1.REDEFINE 1 Trial (2024). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine2025
Phase 3 trial demonstrating 22.7% mean weight loss with CagriSema combination at 68 weeks vs 11.8% monotherapy and 16.1% semaglutide alone.
- 2.
- 3.
- 4.
Safety Profile
Common Side Effects
- Nausea — most common, typically mild to moderate and transient during titration
- Vomiting — especially during dose escalation
- Diarrhea or constipation
- Decreased appetite (intended effect, but can be excessive in some users)
- Injection site reactions: redness, swelling, mild pain
- Acute cholelithiasis (gallstones) — reported at higher doses; weight loss itself elevates gallstone risk
- Fatigue, particularly early in protocol
- Headache
- Nausea
- Diarrhea
- Injection site reactions
Contraindications
- Personal or family history of medullary thyroid carcinoma (theoretical, based on calcitonin receptor agonism)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to cagrilintide or any excipients
- Pregnancy and breastfeeding (insufficient safety data)
- Severe gastroparesis (gastric emptying slowing may worsen condition)
- History of pancreatitis (theoretical elevated risk with metabolic peptides)
- MTC history
- MEN 2
Pre-Use Screening Checklist
Calcitonin receptor agonism raises theoretical concern for calcitonin-secreting thyroid tumors. Baseline calcitonin and thyroid ultrasound advised in those with thyroid nodules or family history of MTC.
Rapid weight loss and calcitonin receptor activity may increase gallstone risk. Baseline gallbladder ultrasound recommended if history of gallbladder disease.
Gastric emptying slowing effect is contraindicated in those with confirmed gastroparesis.
History of pancreatitis warrants caution. Lipase and amylase monitoring during treatment if any abdominal symptoms develop.
Fasting glucose, HbA1c, lipid panel, and body composition metrics provide baseline for tracking metabolic response.
Legal & Regulatory Status
Not approved. Investigational; NDA for CagriSema (fixed-dose combination with semaglutide) submitted to FDA by Novo Nordisk in December 2025 based on REDEFINE 1 results. FDA review expected 2026. Cagrilintide monotherapy remains investigational.
Not specifically listed. Not relevant to competitive sports context as a metabolic/weight management compound.
Not approved. Research compound status.
Not approved. Under clinical development by Novo Nordisk. EMA submission anticipated following FDA review.
Not approved by TGA. Research compound.
Research Protocols
Dosing Protocols
Standard weight loss titration
SubcutaneousCagriSema combination protocol
SubcutaneousRoutes of Administration
Subcutaneous injection
Most commonInjected into the abdomen, thigh, or upper arm subcutaneous tissue using a small insulin-type syringe.
Rotate injection sites weekly. Abdomen is the most commonly reported site in community use.
Reconstitution Guide
Bacteriostatic water (BAC water) preferred; sterile water acceptable
Add BAC water slowly to the lyophilized powder vial, swirl gently — do not shake. Allow to dissolve completely at room temperature.
For a 5 mg vial: add 2 mL BAC water = 2.5 mg/mL. A 2.4 mg dose = 0.96 mL drawn.
Refrigerate at 2–8°C. Use within 28 days. Do not freeze reconstituted solution.
Store lyophilized powder at -20°C long-term or 2–8°C short-term. Protect from light and heat.
Once-weekly dosing means timing relative to meals is not critical. Many users pick a consistent day of the week. Administer at the same time each week for best consistency.
Pharmacokinetics
| Half-Life | Approximately 7 days, enabling once-weekly dosing. Extended half-life achieved via C-20 fatty diacid albumin binding, similar in design to semaglutide's albumin-binding mechanism. |
| Absorption | Subcutaneous absorption with slow release into circulation. Peak plasma concentration typically reached within 24–72 hours post-injection. |
| Distribution | Distributed throughout systemic circulation bound to albumin. Reaches key targets including hypothalamic appetite centers, GI tract, and pancreatic tissue. |
| Metabolism | Proteolytic degradation following standard peptide catabolism pathways. Fatty acid side chain and amino acid substitutions (Pro25, Pro28, Pro29) resist enzymatic breakdown and prevent amyloid aggregation. |
| Molecular Structure | 37-amino acid lipidated amylin analog. Key modifications: Pro substitutions at positions 25, 28, 29, 37; Tyr37→Pro; Asn14→Glu; Val17→Arg; C-20 fatty diacid via alpha-glutamyl spacer; disulfide bridge between Cys2 and Cys7; C-terminal amidation. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Body weight and compositionTrack weight loss rate. Excessive loss (>1.5 kg/week sustained) may indicate need to reduce dose.Check: Weekly
- GI symptomsNausea, vomiting, constipation. Persistent vomiting that limits food intake warrants dose reduction or pause.Check: Ongoing
- Gallbladder symptomsRight upper quadrant pain, especially postprandial. Investigate with ultrasound if persistent.Check: As symptoms arise
- Blood glucose (if diabetic or pre-diabetic)Dose adjustments of concurrent diabetes medications may be needed as metabolic function improves.Check: Regular CGM or periodic fasting glucose
Critical Warning Signs
- Severe persistent abdominal pain, especially radiating to the backDiscontinue and seek medical evaluation. Could indicate pancreatitis.Urgency: IMMEDIATE
- Right upper quadrant pain or jaundiceEvaluate for cholelithiasis or cholecystitis. Suspend use pending evaluation.Urgency: Within 24-48 hours
- Persistent vomiting preventing adequate nutrition or hydrationReduce dose or pause protocol. Monitor for dehydration.Urgency: Within 24-48 hours
- Rapidly growing thyroid nodule or neck swellingThyroid evaluation including calcitonin levels and ultrasound.Urgency: Within 1 week if persistent
Featured in Stacking Protocols
Community-researched combinations involving this compound
Semaglutide (Ozempic/Wegovy)
CagriSemaSuperior weight loss via complementary appetite pathways
Amylin receptor agonism (cagrilintide) + GLP-1 receptor agonism (semaglutide) act on distinct but converging hypothalamic circuits. The combination produces greater appetite suppression, more pronounced gastric emptying delay, and additive weight loss effect.
2.4 mg cagrilintide + 2.4 mg semaglutide, both once weekly sub-Q, titrated in parallel from low starting doses over 16 weeks.
Retatrutide
Retatrutide Synergy StackTheoretical maximum weight loss via 4-pathway metabolic combination
Retatrutide activates GLP-1, GIP, and glucagon receptors; adding cagrilintide adds amylin receptor agonism as a fourth distinct pathway. Purely theoretical in community — no formal clinical data on this combination exists.
Experimental; community members using retatrutide at therapeutic doses (2–12 mg/week) sometimes add cagrilintide 0.5–1.0 mg/week. Start low given compounding GI effects.
Tirzepatide (Mounjaro/Zepbound)
Tirzepatide (Mounjaro/Zepbound) Synergy StackEnhanced satiety and metabolic control
Tirzepatide's dual GLP-1/GIP agonism combined with cagrilintide's amylin pathway agonism targets three receptor systems. Community reports suggest additive satiety effects.
Tirzepatide at standard titration doses; cagrilintide added at 0.25–0.5 mg/week initially. GI effects can be significant — titrate cautiously.